Abstract Motivation Gene set analysis (GSA) is a foundational approach for interpreting genomic data of diseases by linking genes to biological processes. However, conventional GSA methods overlook clinical context of the analyses, often generating long lists of enriched pathways with redundant, nonspecific, or irrelevant results. Interpreting these requires extensive, ad-hoc manual effort, reducing both reliability and reproducibility. Results We introduce cGSA, a novel AI-driven framework that enhances GSA by incorporating context-aware pathway prioritization. cGSA integrates gene cluster detection, enrichment analysis, and large language models to identify pathways that are not only statistically significant but also biologically meaningful. Benchmarking on 102 curated gene sets across 19 diseases and ten disease-related biological mechanisms shows that cGSA outperforms baseline methods by over 30%, with expert validation confirming its increased precision and interpretability. Two independent case studies in melanoma and breast cancer further demonstrate its potential to uncover context-specific insights and support targeted hypothesis. Availability and Implementation The demo website is publicly available at https://www.ncbi.nlm.nih.gov/CBBresearch/Lu/Demo/cGSA/, while the data and code can be accessed at https://github.com/ncbi-nlp/cGSA.
The Gene Ontology (GO) is a public resource that describes gene functions and characteristics through a structured vocabulary of standardised terms. It currently contains annotations for over 1.5 million gene products, each linked to one or more GO terms. In this study, we propose integrating this GO-based semantic structure into machine learning systems for medical diagnostics. This approach serves a dual purpose: first, to prioritise genes that are semantically relevant to a given clinical task, thereby refining model input; and second, to enable the analysis of biologically predefined gene sets, which may reveal novel mechanisms underlying disease.
Evaluated across 16 benchmark data sets spanning diverse medical domains, our GO term-informed gene selection method generally outperformed models trained on full gene sets. Further analysis of individual GO terms not only enhanced classification performance but also identified high-performing, task-specific gene subsets that were overlooked during initial gene selection.
Our findings demonstrate that Gene Ontology can be effectively leveraged for semantics-aware gene selection in clinical machine learning. Moreover, systematically evaluating individual GO terms offers a scalable strategy to uncover new, testable biological hypotheses–revealing gene functions that might otherwise remain hidden when examining only broadly selected gene combinations.
Peter Eckhardt-Bellmann, N. Taha, Silke D. Werle et al.· BMC Bioinformatics· 0 citations
Gene Ontology (GO) enrichment analysis is a foundational tool for translating large-scale genomic data into biological insights, but typically yields hundreds of redundant terms that obscure overarching themes. Existing summarization tools rely on fixed similarity metrics (REVIGO, GOSemSim, clusterProfiler::simplify()), gene-overlap measures (Metascape), or static hierarchy mappings (GO-slim), and therefore cannot incorporate biological context. Manual curation provides context-aware grouping but is subjective and labor-intensive. A scalable, context-aware framework is needed to cluster GO terms into interpretable higher-order biological domains. Here we present LLMBDC (Large Language Model for Biological Domains Oriented Clustering of Gene Ontology), a training-free framework that leverages zero-shot semantic reasoning of LLMs with confidence scoring to cluster GO terms into BioDomains using only ontology information at inference time. Benchmarked across Alzheimer's disease (AD) and Fragile X syndrome (FXS) against six baseline methods including SapBERT, LLMBDC achieved substantially higher precision, recall, and clustering performance. Against ground-truth annotations, LLMBDC improved ARI from 9.7% to 73.3% (AD) and from 15.7% to 66.6% (FXS) over REVIGO, with corresponding NMI gains from 59.9% to 73.4% (AD) and 66.0% to 79.5% (FXS). A Cauchy combination test further confirmed that aggregated BioDomains retained statistically significant functional signals. LLMBDC provides a scalable, reproducible, and interpretable route to context-aware, system-level interpretation of GO enrichment results while preserving biological specificity.
This work presents a scalable, reproducible framework for evaluating, optimizing, and interpreting LLMs for biomedical knowledge extraction, with a focus on gene–gene regulatory relation prediction, pathway component recognition, multimodal pathway figure understanding, and automated prompt optimization.
The rapid expansion of the oncology literature has outpaced manual curation of clinically relevant gene-cancer-drug associations and oncogenic driver evidence. Existing automated approaches often lack transparency or are difficult to scale across heterogeneous data sources. To address this gap, we developed megaMine, a transparent, rule-based, and context-aware literature-mining framework that integrates therapeutic and driver evidence from PubMed, PubTator, and Europe PMC by combining entity recognition, hierarchical heuristics, and contextual labeling. In therapy mode, megaMine was applied to approximately 100,000 oncology articles published between 2015 and 2025, yielding more than 23,000 structured sentence-level evidence records, with standardized annotations for drug response, resistance, and study context. Internal evaluation of context labels showed the strong separability between efficacy and non-efficacy evidence using ridge logistic regression (AUROC = 0.915; AUPRC = 0.941). Benchmarking against NCI/OncoKB-supported drug-cancer associations showed that curated clinical associations had higher megaMine composite evidence scores than unlabeled comparison pairs [median (IQR): 25.6 (9.07-72.5) vs. 3.61 (1.69-8.69); Wilcoxon rank-sum test, P < 2.2 × 10−16]. In driver mode, megaMine retrieved mutation- and biomarker-related evidence from an ERBB-focused gastric cancer query, generating 750 evidence rows from 200 PMIDs. These results demonstrate that deterministic and interpretable approaches can support scalable evidence extraction for downstream applications such as knowledge graph construction and literature-based evidence synthesis.
Muhammad Junaid, K. Prazanowska, Ha-Eun Jeong et al.· bioRxiv· 0 citations
An embedding-based statistical framework is developed that transforms gene and function descriptions into vector representations, enabling statistical testing of gene-gene and gene-function relationships and quantitative prioritization of de novo functional hypotheses inferred by LLMs.